Top

Supportive Care in Cancer

Published in:

01-01-2012 | Original Article

Factors influencing quality of life in patients with benign primary brain tumors: prior to and following surgery

Authors: Shiow-Luan Tsay, Jui-Yen Chang, Patsy Yates, Kuan-Chia Lin, Shu-Yuan Liang

Published in: Supportive Care in Cancer | Issue 1/2012

Abstract

Goals

Few studies have repeatedly evaluated quality of life and potentially relevant factors in patients with benign primary brain tumor. The purpose of this study was to explore the relationship between the experience of the symptom distress, functional status, depression, and quality of life prior to surgery (T₁) and 1 month post-discharge (T₂).

Patients and methods

This was a prospective cohort study including 58 patients with benign primary brain tumor in one teaching hospital in the Taipei area of Taiwan. The research instruments included the M.D. Anderson Symptom Inventory, the Functional Independence Measure scale, the Hospital Depression Scale, and the Functional Assessment of Cancer Therapy-Brain.

Results

Symptom distress (T₁: r = −0.90, p < 0.01; T₂: r = −0.52, p < 0.01), functional status (T₁: r = 0.56, p < 0.01), and depression (T₁: r = −0.71, p < 0.01) demonstrated a significant relationship with patients' quality of life. Multivariate analysis identified symptom distress (explained 80.2%, R _inc ² = 0.802, p = 0.001) and depression (explained 5.2%, R _inc ² = 0.052, p < 0.001) continued to have a significant independent influence on quality of life prior to surgery (T₁) after controlling for key demographic and medical variables. Furthermore, only symptom distress (explained 27.1%, R _inc ² = 0.271, p = 0.001) continued to have a significant independent influence on quality of life at 1 month after discharge (T₂).

Conclusions

The study highlights the potential importance of a patient's symptom distress on quality of life prior to and following surgery. Health professionals should inquire about symptom distress over time. Specific interventions for symptoms may improve the symptom impact on quality of life. Additional studies should evaluate symptom distress on longer-term quality of life of patients with benign brain tumor.

Department of Health, Bureau of Health Promotion, Taiwan, ROC (2010) Research & statistic. Available at http://www.bhp.doh.gov.tw/BHPnet/Portal/StatisticsShow.aspx?No=200911300001. Access 5 June 2010

Armstrong TS, Cohen MZ, Eriksen LR, Hickey JV (2004) Symptom clusters in oncology patients and implication for symptom research in people with primary brain tumor. J Nurs Sch 36:197–206CrossRef

Pelletier G, Verhoef MJ, Khatri N, Hagen N (2002) Quality of life in brain tumor patients: the relative contributions of depression, fatigue, emotional distress, and existential issues. J Neuro Oncol 57:41–49CrossRef

Bosma I, Reijneveld JC, Douw L, Vos MJ, Postma TJ, Aaronson NK, Muller M, Vandertop WP, Slotman MJ, Taphoorn JB, Heimans JJ, Klein M (2009) Health-related quality of life of long-term high-grade glioma survivors. Neuro Oncol 11:51–58PubMedCrossRef

Sehlen S, Lenk M, Hollenhorst H et al (2003) Quality of life as a predictive mediator variable for survival in patients with intracerebral neoplasma during radiotherapy. Onkologie 26:38–43PubMedCrossRef

Mukand JA, Blackinton DD, Crincoli M, Lee JJ, Santos BB (2001) Incidence of neurologic deficits and rehabilitation of patients with brain tumors. Am J Phys Med Rehabil 80:346–350PubMedCrossRef

Ullrich NJ, Scott RM, Pomeroy SL (2005) Craniopharyngioma therapy: long term effects on hypothalamic function. Neurologist 11:55–60PubMedCrossRef

Giovagnli AR (1999) Quality of life in patients with stable disease after surgery, radio-therapy, and chemotherapy for malignant brain tumor. J Neurol Neurosurg Psychiatry 67:358–363CrossRef

Liu L, Fiorentino L, Natarajan L, Parker BA, Mills P, Sadler GR, Dimsdale JE, Rissling M, He F, Ancoli-Israel S (2009) Pre-treatment symptom cluster in breast cancer patients is associated with worse sleep, fatigue and depression during chemotherapy. Psycho Oncol 18:187–194CrossRef

10.

Mackworth N, Fobair P, Prados MD (1992) Quality of life self-reports from 200 brain tumor patients: comparisons with Karnofsky scores. J Neuro Oncol 14:243–253CrossRef

11.

Cleeland CS, Mendoza TR, Wang XS et al (2000) Assessing symptom distress in cancer patients: the M. D. Anderson Symptom Inventory. Cancer 89:1634–1646PubMedCrossRef

12.

Lin CC, Chang AP, Cleeland CS, Mendoza TR, Wang XS (2007) Anderson symptom inventory: symptom assessment in cancer patients. J Pain Symptom Manag 33:180–188CrossRef

13.

Hamilton BB, Granger CV, Sherwin FS et al (1987) A uniform national data system for medical rehabilitation. In: Fuhrer MJ (ed) Rehabilitation outcomes: analysis and measurement. Brookes, Baltimore, pp 137–147

14.

Ottenbacher KKJ, Hsu Y, Granger C, Fiedler R (1996) The reliability of the functional independence measure: a quantitative review. Arch Phys Med Rehab 77:1226–1232CrossRef

15.

Liaw LJ (2000) Reliability and validity of the interview based functional independence measure in patients with stroke. Kaohsiung Medical University, Kaohsiung

16.

Bjelland I, Dahl AA, Haug TT, Neckelmann D (2002) The validity of the hospital anxiety and depression scale: an updated literature review. J Psychosom Res 52:69–77PubMedCrossRef

17.

Zigmond A, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361–370PubMedCrossRef

18.

Weitzner MA, Meyers CA, Gelke CK, Byrne KS, Cella DF, Levin VA (1995) The functional assessment of cancer therapy (FACT) scale: development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumor. Cancer 75:1151–1161PubMedCrossRef

19.

One ZH (2006) The evaluation of Chinese version of functional assessment of cancer therapy (FACT). J Pract Oncol 21:77–80

20.

Kenefick AL (2006) Patterns of symptom distress in older women after surgical treatment for breast cancer. Oncol Nurs Forum 33:327–335PubMedCrossRef

21.

Lovrics PJ, Cornacchi SD, Barnabi F, Whelan T, Goldsmith CH (2008) The feasibility and responsiveness of the health utilities index in patients with early-stage breast cancer: a prospective longitudinal study. Qual Life Res 17:333–345PubMedCrossRef

22.

Quintard B, Lakdja F (2008) Assessing the effect of beauty treatments on psychological distress, body image, and coping: a longitudinal study of patients undergoing surgical procedures for breast cancer. Psycho Oncol 17:1032–1038CrossRef

23.

Mundy EA, Blanchard EB, Cirenza E et al (2000) Posttraumatic stress disorder in breast cancer patients following autologous bone marrow transplantation or conventional cancer treatment. Behav Res Ther 38:1015–1027PubMedCrossRef

24.

Armstrong TS, Gning I, Mendoza TR, Weinberg JS, Gilbert MR, Tortorice ML, Cleeland CS (2009) Clinical utility of the MDASI-BT in patients with brain metastases. J Pain Symptom Manag 37:331–340CrossRef

25.

Chang VT, Hwang SS, Feuerman M, Kasimis BS (2000) Symptom and quality of life survey of medical oncology patients at a veteran affairs medical center: a role for symptom assessment. Cancer 88:1175–1183PubMedCrossRef

26.

Portenoy RK, Thaler HT, Kornblith AB et al (1994) Symptom prevalence, characteristics and distress in a cancer population. Qual Life Res 3:183–189PubMedCrossRef

27.

Anderson SI, Taylor R, Whittle IR (1999) Mood disorders in patients after treatment for primary intracranial tumors. Br J Neurosurg 13:480–485PubMed

28.

Chung JWY, Wong TKS, Yang JCS (2000) The lens model: assessment of cancer pain in a Chinese context. Cancer Nurs 23:454–461PubMedCrossRef

29.

Huang ME, Wartella JE, Kreutzer JS (2001) Functional outcomes and quality of life in patients with brain tumor: a preliminary report. Arch Phys Med Rehab 82:1540–1546CrossRef

30.

Pit-ten Cate IM, Kennedy C, Stevenson J (2002) Disability and quality of life in spina bifida and hydrocephalus. Dev Med Child Neurol 44:317–322CrossRef

31.

Fisch MJ, Loehrer PJ, Kristeller J et al (2003) Fluoxetine versus placebo in advanced cancer outpatients: a double-blind trial of the Hoosier Oncology Group. J Clin Oncol 21:1937–1943PubMedCrossRef

32.

Molassiotis A, Sylt P, Diggins H (2006) The management of cancer- related fatigue after chemotherapy with acupuncture and acupressure: a randomized controlled trial. Complement Ther Med 15:228–237PubMedCrossRef

33.

Salander P, Bergenheim AT, Henriksson R (2000) How was life after treatment of a malignant brain tumor? Soc Sci Med 51:589–598PubMedCrossRef

34.

Savard J, Simard S, Giquere I et al (2006) Randomized clinical trial on cognitive therapy for depression in women with metastatic breast cancer: psychological and immunological effects. Palliat Support Care 4:219–237PubMedCrossRef

35.

Strang S, Strang P (2001) Spiritual thoughts, coping and “sense of coherence” in brain tumor patients and their spouses. Palliat Med 15:127–134PubMedCrossRef

36.

Williams S, Dale J (2006) The effectiveness of treatment for depression/depressive symptoms in adults with cancer: a systematic review. Br J Cancer 94:372–390PubMedCrossRef

37.

Nei-Dwyer G, Lang DA, Davis A (2000) Outcome from complex neurosurgery: an evidence based approach. Acta Neurochir 142:367–371CrossRef

38.

Kelleher MO, Fernandes MF, Sim DW, O'sullivan MG (2002) Health-related quality of life in patients with skull base tumors. Br J Neurosurg 16:16–20PubMedCrossRef

39.

Mainio A, Tuunanen S, Hakko H et al (2006) Decreased quality of life and depression as predictors for shorter survival among patients with low-grade gliomas: a follow-up from 1990 to 2003. Eur Arch Psychiatry Clin Neurosci 256:516–521PubMedCrossRef

Title: Factors influencing quality of life in patients with benign primary brain tumors: prior to and following surgery
Authors: Shiow-Luan Tsay
Jui-Yen Chang
Patsy Yates
Kuan-Chia Lin
Shu-Yuan Liang
Publication date: 01-01-2012
Publisher: Springer-Verlag
Published in: Supportive Care in Cancer / Issue 1/2012
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-010-1053-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Goals

Patients and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2012

Neurocognitive function in head and neck cancer patients prior to treatment

Pediatric patients with a malignant bone tumor: when does functional assessment make sense?

Examining the introduction of a supportive care screening and referral process for cancer patients: how does practice compare with protocols?

Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study

Health economics of a palliative care unit for terminal cancer patients: a retrospective cohort study

Switching from oxycodone to methadone in advanced cancer patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer